Objective We aimed to evaluate SIGLEC1 (CD169) as a biomarker in Multiple Sclerosis
(MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the specificity of …

We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and
Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of …

Background: Sialic acid binding immunoglobulin-like lectins (Siglecs) are cell surface
receptors that recognize sialic acids and may attenuate immune responses and reduce …

Background: Phagocytes, such as macrophages and microglia, are key effector cells in the
pathophysiology of multiple sclerosis (MS). It is widely accepted that they instigate and …

Background and Objectives The aim of this study was to identify novel biomarkers for
multiple sclerosis (MS) diagnosis and prognosis, addressing the critical need for specific …

Siglecs (Sialic acid-binding immunoglobulin-type lectins) are a I-type lectin that typically
binds sialic acid. Siglecs are predominantly expressed in immune cells and generate …

Myeloid derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell
population that is increased under various pathological conditions, including cancer. In …

Sialic acid immunoglobulin-like lectin E (Siglec-E) is a subtype of pattern recognition
receptors found on the surface of myeloid cells and functions as a key immunosuppressive …

Multiple Sclerosis (MS) is a chronic inflammatory disease of the CNS which is characterized
by large mononuclear cell infiltration and significant demyelination. CXCL8 is a chemo …

Multiple sclerosis (MS) is an inflammatory demyelinating disease often characterized by
remission and relapse periods occurring at irregular intervals after an initial attack (clinically …